National Coverage Analysis of CAR-T Therapies — Policy, Evidence, and Payment

Even if CMS concludes that CAR-T therapy provides a net benefit for Medicare patients, it could limit who can provide the therapy, require collection of further outcome data, limit coverage to clinical trials, and design a payment approach promoting price competition.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2018-10, Vol.379 (15), p.1396-1398
1. Verfasser:	Bach, Peter B
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens Antigens, CD19 Cell- and Tissue-Based Therapy - economics Clinical trials Competition Confidence Cost control Drug dosages FDA approval Humans Immunotherapy - economics Insurance Coverage Lymphoma Lymphoma, Non-Hodgkin - therapy Medicaid Medicare Patients Profits Receptors, Antigen, T-Cell - therapeutic use Reimbursement Mechanisms Remission Induction T-Lymphocytes - transplantation Trump, Donald J United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Even if CMS concludes that CAR-T therapy provides a net benefit for Medicare patients, it could limit who can provide the therapy, require collection of further outcome data, limit coverage to clinical trials, and design a payment approach promoting price competition.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMp1807382